{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-25-000009","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.669474+00:00","generated_at":"2026-05-17T05:04:41.948080+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Avalo Therapeutics expands leadership with CBO and SVP HR appointments","bullets":["Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.","Ashley Ivanowicz appointed SVP, Human Resources; receives 100k stock option inducement grant.","Both options vest over 4 years with 12-month cliff; granted under Nasdaq inducement rule.","Company advancing AVTX-009 in Phase 2 LOTUS trial for hidradenitis suppurativa; data readout expected mid-2026.","Boyd previously led BD at Longboard, culminating in $2.6B acquisition by Lundbeck."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-25-000009","json":"https://secwatch.observer/filing/0001534120-25-000009.json","markdown":"https://secwatch.observer/filing/0001534120-25-000009.md","text":"https://secwatch.observer/filing/0001534120-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/0001534120-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/avtx-20250929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:04:41.948080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}